BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $100.79 Average Target Price from Brokerages

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) have been assigned an average rating of “Moderate Buy” from the twenty-three analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $101.5263.

BBIO has been the subject of several recent analyst reports. Piper Sandler raised their target price on shares of BridgeBio Pharma from $111.00 to $115.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Weiss Ratings lowered shares of BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Raymond James Financial downgraded shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $110.00 price objective on shares of BridgeBio Pharma in a research note on Tuesday, August 11th. Finally, Bank of America lifted their price objective on shares of BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th.

Insiders Place Their Bets

In related news, Director Jennifer E. Cook sold 148,589 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $88.54, for a total value of $13,156,070.06. Following the completion of the sale, the director directly owned 8,383 shares of the company’s stock, valued at approximately $742,230.82. This represents a 94.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $84.00, for a total value of $1,442,028.00. Following the sale, the director owned 22,579 shares of the company’s stock, valued at $1,896,636. The trade was a 43.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 347,343 shares of company stock valued at $27,591,000 over the last quarter. 14.23% of the stock is owned by insiders.

Institutional Trading of BridgeBio Pharma

A number of hedge funds have recently made changes to their positions in BBIO. Jupiter Topco LLC purchased a new position in BridgeBio Pharma during the second quarter valued at approximately $1,050,762,000. Janus Henderson Group PLC lifted its position in BridgeBio Pharma by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after buying an additional 2,178,556 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of BridgeBio Pharma by 7,463.2% during the 2nd quarter. California State Teachers Retirement System now owns 12,532,377 shares of the company’s stock valued at $933,411,000 after buying an additional 12,366,674 shares during the period. Farallon Capital Management LLC boosted its stake in shares of BridgeBio Pharma by 9.8% during the 4th quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock valued at $688,292,000 after buying an additional 806,463 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of BridgeBio Pharma by 23.0% during the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after acquiring an additional 902,648 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and raised its price target to $120, implying substantial upside from the recent trading level. The target reflects continued analyst confidence in BridgeBio’s commercial products and development pipeline. Benzinga report
• Positive Sentiment: BridgeBio will present new oral infigratinib data at the 2026 ESPE meeting, including late-breaking PROPEL 3 results on medical complications associated with achondroplasia. Longer-term efficacy and safety data, an infant and toddler study update, and hypochondroplasia research will also be presented, providing potential visibility ahead of important pipeline catalysts. BridgeBio ESPE presentation announcement
• Positive Sentiment: BridgeBio reached an agreement with the U.S. government to expand Medicaid access to Attruby. Broader reimbursement access could support adoption and commercial revenue for the company’s marketed therapy, although the financial impact was not quantified in the reports. Attruby Medicaid access article

BridgeBio Pharma Stock Down 0.1%

Shares of NASDAQ BBIO opened at $76.50 on Friday. The stock’s fifty day simple moving average is $80.54 and its 200 day simple moving average is $73.61. The stock has a market capitalization of $14.95 billion, a price-to-earnings ratio of -21.43 and a beta of 0.97. BridgeBio Pharma has a 52-week low of $48.78 and a 52-week high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. The firm’s revenue was up 120.4% compared to the same quarter last year. During the same period last year, the company posted ($0.95) earnings per share. As a group, analysts anticipate that BridgeBio Pharma will post -2.62 earnings per share for the current year.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.